Notably, in a subgroup of 32 GC patients with moderate-to-high (IHC 2+/3+) CLDN18.2 expression in ≥25% of tumor cells, the ORR and DCR rose to 71.9% (95% CI: 53.3–86.3%) and 96.9% (95% CI: 83.3–99.9%), respectively. This evidence concerns the gene CLDN18 and neoplasm.